Vasoactive intestinal peptide COVID research focuses on aviptadil and lung inflammation. Learn what studies found, safety concerns, and current FDA status.
Vasoactive intestinal peptide (VIP) is a naturally occurring 28-amino-acid signaling molecule that relaxes blood vessels, opens airways, and dampens inflammation. During the COVID-19 pandemic, researchers tested a synthetic form of VIP called aviptadil (RLF-100) in patients with severe respiratory failure. The results have been mixed, and no VIP-based product has been approved by the FDA to treat COVID-19.
What Is Vasoactive Intestinal Peptide?
VIP is a neuropeptide found throughout the gut, the nervous system, and the lungs. It was first isolated from the small intestine in the 1970s, which is where the "intestinal" part of the name comes from, even though most of its medical interest today involves the airways.
VIP works by binding to two receptors, VPAC1 and VPAC2, that sit on the surface of many cell types. When VIP attaches to those receptors, it triggers a cascade that:
- Relaxes smooth muscle in blood vessels and bronchial tubes
- Increases blood flow to the lungs
- Reduces the release of inflammatory cytokines such as TNF-alpha and IL-6
- Supports alveolar type II cells, which produce surfactant and help keep air sacs open
Those last two points are the reason VIP became a candidate for COVID-19 research. Severe COVID-19 is driven by inflammation and by damage to the alveolar epithelium, and VIP touches both processes.
Why Researchers Looked at VIP for COVID-19
Early in the pandemic, scientists noticed that SARS-CoV-2 attacks alveolar type II cells, the same cells that express VIP receptors and produce surfactant. That overlap suggested VIP might help protect the lung tissue the virus targets.
There were also broader anti-inflammatory reasons for interest. In critical COVID-19, an overactive immune response can flood the lungs with cytokines and fluid, a pattern often described as a cytokine storm. VIP has been shown in laboratory and animal studies to calm several of the pathways involved in that response.
Finally, VIP is short-lived in the bloodstream, so an inhaled or intravenous formulation can deliver the peptide directly to the lungs. That localized delivery was the rationale behind aviptadil, the synthetic version of VIP used in clinical trials.
Aviptadil (RLF-100) and the COVID-19 Trials
Aviptadil is a synthetic, stabilized form of VIP. It was developed by NeuroRx and Relief Therapeutics and tested in hospitalized COVID-19 patients with respiratory failure. The trial landscape changed quickly, and several studies were small, uncontrolled, or stopped early.
| Study or product | Population | Route | Reported outcome | Status |
|---|---|---|---|---|
| Aviptadil (RLF-100) | Critical COVID-19 with respiratory failure | Inhaled or IV | Early case reports described recovery; larger analyses did not consistently confirm a survival benefit | Not approved; emergency use request declined by the FDA in 2021 |
| Aviptadil (TESICO trial) | Adults with acute hypoxemic respiratory failure | IV | No significant improvement in the primary recovery endpoint | Research only |
| Standard care plus corticosteroids | Hospitalized COVID-19 patients | Oral or IV | Mortality benefit demonstrated in large randomized trials | Recommended by treatment guidelines |
The takeaway from the table is straightforward: VIP generated genuine scientific interest, but it never crossed the threshold of proven benefit that corticosteroids did.
What the Evidence Shows So Far
- Vasoactive intestinal peptide is a legitimate signaling molecule with well-documented effects on the lungs and blood vessels.
- Aviptadil, the synthetic VIP studied for COVID-19, has not been approved by the FDA for any COVID-19 indication.
- The largest randomized trial of aviptadil in respiratory failure did not show a clear benefit on its primary endpoint.
- No VIP product is currently recommended by major clinical guidelines for the treatment or prevention of COVID-19.
- Small, uncontrolled studies and company press releases should not be treated as proof that VIP works for COVID-19.
Safety, Side Effects, and Legal Status
VIP is a prescription-grade peptide that must be given by injection or inhalation under medical supervision. Reported side effects include low blood pressure, flushing, rapid heart rate, headache, nausea, and diarrhea. Because VIP dilates blood vessels, it can be risky for people who already have low blood pressure or heart conditions.
No oral VIP supplement has been shown to work, and products marketed as "VIP capsules" are not backed by clinical evidence. In the United States, VIP is not an approved drug for COVID-19, and research-grade versions sold online are not manufactured under FDA oversight.
Anyone considering a VIP product for a health condition should talk with a licensed healthcare professional first, especially if they take blood pressure medication.
Reading VIP and Other Peptide Claims Critically
Online interest in peptides often spills across unrelated categories. Questions such as what is semax peptide used for have nothing to do with COVID-19, and each peptide has its own research history, dosing conventions, and risk profile.
A peptide dosing calculator can help laboratory researchers convert units, but it cannot tell you whether a compound is appropriate for a particular illness. Similarly, anyone searching where to buy ss-31 peptide should know that research-grade peptides sold online are not FDA-approved medicines.
The same pattern shows up in pt-141 peptide reviews, where a handful of enthusiastic testimonials are often presented as if they were clinical evidence. Marketing language is not a substitute for randomized trials.
The Bottom Line on Vasoactive Intestinal Peptide and COVID
VIP is a real molecule with real biology, and it was a reasonable hypothesis to test against COVID-19. Testing a hypothesis, however, is not the same as proving a treatment.
Aviptadil did not deliver consistent, reproducible benefits in COVID-19 trials, and it is not approved for that use. If you have questions about COVID-19 prevention or treatment, the reliable options are vaccination, guidance from a clinician, and therapies that have passed large randomized trials.
Frequently Asked Questions
Does vasoactive intestinal peptide treat COVID-19?
No. Vasoactive intestinal peptide has been studied as an experimental treatment for severe COVID-19, but it has not been approved by the FDA and did not show consistent benefit in randomized trials. It should never be used as a substitute for proven COVID-19 treatments.
What is aviptadil and is it approved for COVID-19?
Aviptadil is a synthetic form of vasoactive intestinal peptide that was developed under the research name RLF-100. It was tested in hospitalized patients with respiratory failure, but the FDA declined an emergency use authorization in 2021 and the drug is not approved for COVID-19.
Can you buy vasoactive intestinal peptide online?
Some vendors sell research-grade VIP, but these products are not FDA-approved for human use and their purity, sterility, and dosing are not verified. Buying peptides online carries real risks, including contamination and incorrect dosing, so talk with a healthcare professional instead.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.